Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 8/20 | 0.41 |
| ▸ | EIF4A3 | P38919 | 10/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699645 | 0.86 | MEN1 (0.43) | MEN1KMT2AMDM2ACHE | |
| SCHEMBL13699633 | 0.86 | AKR1C3 (0.48) | MEN1KMT2AMDM2 | |
| SCHEMBL13699637 | 0.85 | MDM2 (0.47) | MDM2EIF4A3 | |
| SCHEMBL13699634 | 0.84 | MDM2 (0.46) | MDM2EIF4A3 | |
| SCHEMBL13699641 | 0.84 | AKR1C3 (0.50) | MEN1KMT2AMDM2 | |
| SCHEMBL4160826 | 0.83 | RIPK1 (0.44) | MEN1KMT2ARXFP1MDM2EIF4A3 | |
| SCHEMBL4160818 | 0.83 | RIPK1 (0.44) | MEN1KMT2ARXFP1MDM2EIF4A3 | |
| SCHEMBL13699657 | 0.82 | MDM2 (0.44) | KMT2AMDM2EIF4A3 | |
| SCHEMBL13699644 | 0.81 | AKR1C3 (0.49) | — | |
| SCHEMBL13699638 | 0.81 | SMN1; SMN2 (0.49) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | MEN1 1455/4885KMT2A 1254/4885RXFP1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.